C. Post

Patients' and clinicians' preferences in adjuvant treatment for high-risk endometrial cancer: Implications for shared decision making.

A. Stiggelbout, E. Schaake, J. Beukema, 2021, Gynecologic oncology.

Long-term toxicity and health-related quality of life after adjuvant chemoradiotherapy or radiotherapy alone for high-risk endometrial cancer in the randomised PORTEC-3 trial.

H. Putter, C. Haie-meder, H. Kitchener, 2020, International journal of radiation oncology, biology, physics.

Efficacy and safety of durvalumab with olaparib in metastatic or recurrent endometrial cancer (phase II DOMEC trial).

H. Putter, T. Bosse, A. Westermann, 2022, Gynecologic oncology.

PARP and PD-1/PD-L1 checkpoint inhibition in recurrent or metastatic endometrial cancer.

T. Bosse, A. Westermann, J. Kroep, 2020, Critical reviews in oncology/hematology.

Prevalence and Prognosis of Lynch Syndrome and Sporadic Mismatch Repair Deficiency in Endometrial Cancer

H. Putter, T. Bosse, L. Mileshkin, 2021, Journal of the National Cancer Institute.

Patterns of re-irradiation for recurrent gliomas and validation of a prognostic score.

J. Verhoeff, C. Kleynen, C. Post, 2019, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

OC-0369: Long-Term Quality of Life after (chemo)radiotherapy for high-risk Endometrial Cancer in PORTEC-3

H. Putter, D. Katsaros, J. Ledermann, 2020 .

Radiotherapy Techniques and Treatment-Related Toxicity in the PORTEC-3 Trial: Comparison of Three-Dimensional Conformal Radiotherapy versus Intensity-Modulated Radiotherapy.

H. Putter, C. Haie-meder, H. Kitchener, 2021, International journal of radiation oncology, biology, physics.